Clinical trial
Exploring the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg…
NCT00416195 · Eisai Co., Ltd., Industry · Completed
Key facts
| NCT number | NCT00416195 |
|---|---|
| Title | Exploring the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Explore the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures |
| Lead sponsor | Eisai Co., Ltd., Industry |
| Collaborators | Eisai Limited Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Epilepsy |
| Intervention type | Drug |
| Interventions | E2007, Placebo |
| Enrollment | 48 |
| Start date | Dec 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Dec 27, 2006 |
| Last update posted | Jul 11, 2014 |
| Countries | Latvia |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: